Form 4: Sagimet Biosciences Inc. CEO Acquires Additional Shares
SEC Form 4 Filing
David Happel, President & CEO of Sagimet Biosciences Inc., purchased 12,100 shares of Series A Common Stock at an average price of $5.267 on March 26, 2024.
Summary
- On March 26, 2024, David Happel, the President & CEO of Sagimet Biosciences Inc., acquired 12,100 shares of Series A Common Stock.
- The purchase was made at a weighted average price of $5.267 per share.
- The prices ranged from $5.24 to $5.2999 per share.
- Following the transaction, Happel directly owns 639,200 shares of Sagimet Biosciences Inc.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider trading. The CEO's purchase is a potentially positive signal, but it's not a major event.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The CEO's purchase of shares may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/26/2024 | Date of the stock transaction (purchase of shares). |
| 03/28/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.